No glycemic benefit from guar administration in NIDDM

Area of Science:

• Dietary interventions and metabolic health
• Clinical nutrition and diabetes management

Background:

• Non-insulin-dependent diabetes mellitus (NIDDM) management often involves lifestyle and pharmacological approaches.
• Maintaining optimal glycemic control is crucial for preventing long-term diabetic complications.

Purpose of the Study:

• To evaluate the efficacy of guar minitablets in improving glycemic control and lipid profiles in NIDDM patients.
• To assess the impact of guar supplementation on postprandial glucose excursions and other metabolic parameters.

Main Methods:

• A randomized crossover study involving 29 NIDDM patients.
• Patients received 5-g guar minitablets or placebo three times daily with meals for 8 weeks.
• Measurements included fasting plasma glucose, postprandial glycemic excursion, glycosylated hemoglobin, C-peptide, and body weight.

Main Results:

• Guar supplementation did not significantly alter postprandial glycemic excursion, glycosylated hemoglobin, basal glucose, C-peptide levels, or body weight.
• A significant reduction in low-density lipoprotein (LDL) cholesterol was observed with guar administration (P < .001).
• Few side effects were reported for both guar and placebo treatments.

Conclusions:

• Guar minitablets are ineffective in improving glycemic control in NIDDM patients with near-normal fasting glucose levels.
• Guar supplementation demonstrates a beneficial effect on lowering LDL cholesterol levels in this patient population.
• Further research may explore guar's role in lipid management for diabetic patients.